Suppr超能文献

基线18F-FDG PET/CT的小脑/肝脏指数用于改善移植后淋巴细胞增生性疾病的预后:一项多中心回顾性研究

Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study.

作者信息

Morland David, Kanagaratnam Lukshe, Hubelé Fabrice, Toussaint Elise, Choquet Sylvain, Kas Aurélie, Caquot Pierre-Ambroise, Haioun Corinne, Itti Emmanuel, Leprêtre Stéphane, Decazes Pierre, Bijou Fontanet, Schwartz Paul, Jacquet Caroline, Chauchet Adrien, Matuszak Julien, Kamar Nassim, Payoux Pierre, Durot Eric

机构信息

Médecine Nucléaire, Institut Godinot, Reims, France.

Laboratoire de Biophysique, UFR de Médecine, Université de Reims Champagne-Ardenne, Reims, France.

出版信息

EJNMMI Res. 2024 May 27;14(1):49. doi: 10.1186/s13550-024-01111-8.

Abstract

BACKGROUND

Besides International Prognostic Index (IPI) score, baseline prognostic factors of post-transplant lymphoproliferative disorders (PTLD) are poorly identified due to the rarity of the disease. New indexes derived from healthy organ uptake in baseline 18F-FDG PET/CT have been studied in immunocompetent lymphoma patients. The aim of this study is to evaluate the performances of the cerebellum-to-liver uptake ratio (denoted as CLIP) as a prognostic factor for PFS and OS. This retrospective multicenter study is based on patients with PTLD included in the K-VIROGREF cohort. The previously published threshold of 3.24 was used for CLIP in these analyses.

RESULTS

A total of 97 patients was included with a majority of monomorphic diffuse large B-cell lymphoma subtype (78.3%). Both IPI score (≥ 3) and CLIP (< 3.24) were significant risk factors of PFS with corresponding hazard ratios of 2.0 (1.0-4.0) and 2.4 (1.3-4.5) respectively. For OS, CLIP was not significant and resulted in a hazard ratio of 2.6 (p = 0.059). Neither IPI score or Total Metabolic Tumor Volume reached significance for OS.

CONCLUSION

CLIP is a promising predictor of PFS and perhaps OS in PTLD. Further prospective studies are needed to confirm these results.

摘要

背景

除国际预后指数(IPI)评分外,由于移植后淋巴组织增生性疾病(PTLD)罕见,其基线预后因素尚未明确。免疫功能正常的淋巴瘤患者中,已对基于基线18F-FDG PET/CT中健康器官摄取情况得出的新指标进行了研究。本研究旨在评估小脑与肝脏摄取比值(记为CLIP)作为无进展生存期(PFS)和总生存期(OS)预后因素的性能。这项回顾性多中心研究基于纳入K-VIROGREF队列的PTLD患者。这些分析中CLIP采用先前公布的3.24阈值。

结果

共纳入97例患者,多数为单形性弥漫性大B细胞淋巴瘤亚型(78.3%)。IPI评分(≥3)和CLIP(<3.24)均为PFS的显著危险因素,相应的风险比分别为2.0(1.0 - 4.0)和2.4(1.3 - 4.5)。对于OS,CLIP不显著,风险比为2.6(p = 0.059)。IPI评分和总代谢肿瘤体积对OS均未达到显著水平。

结论

CLIP是PTLD中PFS以及可能是OS的有前景的预测指标。需要进一步的前瞻性研究来证实这些结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2307/11130085/f965b980a40e/13550_2024_1111_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验